With indication to firm is defunct since 2016, Biovest International, Inc., had been a biotechnology company organized around development of therapeutic cancer vaccines. Operating in two segments - Instrumentation and Vaccine - the company developed and offered BiovaxID, a personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm was also involved in the development, manufacture, and sale of instruments and disposables and engaged in the production and contract manufacturing of biologic drugs and cell production for research institutions. The company manufactured mammalian cell culture products, such as whole cells, recombinant and secreted proteins, and monoclonal antibodies; provides related services to develop cell production process protocols, cell line optimization, cell culture production optimization, and other related services. Acenntia Pharma" Customers include biopharmaceutical and biotechnology companies, medical schools, research facilities, hospitals, and public and private laboratories. Formerly dba Cellex Biosciences, Inc., the firm's name was changed to Biovest International, Inc. in 2001. For the period 2003 - 2011 the firm operated as a subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPIQ) - the latter having a product portfolio featuring targeted therapeutics, specialty sales and marketing, pharmacoeconomic services, product development, and specialty distribution but in Accentia's efforts to come out of Chapter 11, BioVest once again operated as its own entity.
